This validation of CLL-CI is based on a modest sample size (300 patients, 165 with peri-diagnostic TP53 information) and we did not evaluate the prognostic impact of total CIRS score due to the challenge of capturing all CIRS components upon retrospective review. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.